Please assess the completion status of the following clinical trial:

Trial Title: A Registry to Evaluate the Flexitouch System and Flexitouch Plus for Treatment of Head and Neck Lymphedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* A diagnosis of head and/or neck lymphedema~* Must be able and willing to participate in all aspects of the registry and provide informed consent prior to registry participation~* Head and chest measurements within the following:~* Crown of head circumference: ≤ 72 cm~* Chest circumference: ≤ 158 cm~* Prescribed the Flexitouch system or Flexitouch Plus~Exclusion Criteria:~* Uncontrolled hyperthyroidism or parathyroidism (for which endocrinologist recommends against neck compression)~* Carotid sinus hypersensitivity syndrome~* Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness)~* Symptomatic bradycardia in the absence of a pacemaker~* Internal jugular venous thrombosis (within 3 months)~* Increased intracranial pressure or other contraindications to internal or external jugular venous compression~* Acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), or surgical flap less than 6-8 weeks post-operative~* Facial or head and neck dermal metastasis~* Acute facial infection (e.g., facial or parotid gland abscess)~* Any condition in which increased venous and lymphatic return is undesirable~* Heart failure (acute pulmonary edema, decompensated acute heart failure)~* Subject is pregnant or trying to become pregnant~* Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).